Daily Roundup

NHC.ASX CU6.ASX CGF.ASX SFG.ASX ARC.ASX

New Hope Corporation Ltd Reports Solid Operational Performance Despite Lower Earnings

New Hope Corporation Limited (ASX: NHC) has released its half year results for the 2026 financial year, highlighting a period of solid operational performance as the company continues to execute its organic growth plans.

Despite facing a period of recovery at the Bengalla Mine and a lower coal price environment, New Hope's low-cost assets and disciplined approach have enabled the board to declare a fully franked interim dividend of 10.0 cents per ordinary share.

The group's saleable coal production increased by 0.4% to 5.5 million tonnes compared to the previous period. This was driven by a further increase in production at the New Acland Mine as it continues to ramp up to around 5 million tonnes per annum.

However, the company reported a 58.5% decrease in underlying EBITDA to $214.8 million and an 84.0% drop in net profit after tax to $54.3 million. This was largely due to lower realised coal prices, increased prime overburden movement, and lower non-regular gains.

Looking ahead, New Hope is focused on remaining a resilient, low-cost coal producer and continuing to execute its organic growth plans, which will enable the company to continue delivering value to shareholders.

Clarity Pharmaceuticals Presents Positive Co-PSMA Trial Results

Clarity Pharmaceuticals has announced positive results from the Co-PSMA trial, which showed its 64Cu-SAR-bisPSMA imaging agent outperformed the standard-of-care 68Ga-PSMA-11 in detecting prostate cancer recurrence in patients with low PSA levels.

The data was presented at the European Association of Urology (EAU) Congress 2026 and has been accepted for publication in the prestigious European Urology journal.

The trial demonstrated that 64Cu-SAR-bisPSMA had a significantly higher mean lesion count compared to 68Ga-PSMA-11 and identified a greater total number of lesions. It also showed a higher true positive rate and lower false negative rate than the standard-of-care agent.

These results, combined with data from Clarity's other studies, are intended to be submitted to the FDA for market authorization of 64Cu-SAR-bisPSMA in prostate cancer patients with biochemical recurrence.

Challenger Revises Offer to Acquire Pepper Money

Challenger Limited (ASX:CGF) has submitted a revised confidential, non-binding and conditional proposal to acquire Pepper Money Limited (ASX: PPM).

Under the revised proposal, Challenger has reduced the offer price from $2.60 per share to $2.25 per share, less the final fully franked Pepper Money 2025 dividend of 7.8 cents per share and any special dividend.

Challenger states that the revised proposal represents its best and final offer, in the absence of a superior proposal. The discussions remain incomplete, and there is no certainty that the revised proposal will eventuate in a transaction.

Seafarms Group Ltd Suspended from ASX Quotation

Seafarms Group Ltd (SFG) has been suspended from quotation on the Australian Securities Exchange (ASX) due to a breach of Listing Rule 12.2 on financial condition.

The suspension was initially imposed after SFG failed to lodge its Half Year Report for the period ended 31 December 2025. While SFG subsequently lodged the report, the ASX has determined that the company's financial condition is not adequate to warrant the continued quotation of its securities.

The suspension will continue until SFG is able to demonstrate compliance with the Listing Rules and that it is appropriate for the company's securities to be reinstated to quotation.

ARC Funds Ltd Resumes Trading After Board Appointment

ARC Funds Ltd (ASX: ARC) has announced that the suspension of trading in its securities has been lifted following the release of an announcement regarding a board appointment.

No further details about the board appointment were provided in the announcement. The company will now resume trading on the Australian Securities Exchange (ASX) immediately.